age1

age1 funds breakthrough longevity companies addressing the core challenges of the field. We help contrarian founders build generational biotech companies. Our expertise is at the earliest stage possible. We are a next-generation fund accelerating the longevity paradigm shift. We value pragmatism, rigor, and optimism. We’ve backed some of the first longevity biotech companies to IPO and achieve clinical translation. Our vision is to make aging and age-related diseases optional for all.